Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173428 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3174901 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL3170706 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL3176215 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL3160277 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3166727 | 0.91 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3176202 | 0.91 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3160716 | 0.90 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3175763 | 0.90 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3180118 | 0.90 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649095-B2 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-19 | — | — | US | claimed |
| EP-1308440-B1 | PIPERIDINE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2009-05-06 | — | — | EP | claimed |
| US-7109342-B2 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | claimed |
| US-20060189656-A1 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-08-24 | — | — | US | claimed |
| US-20040044036-A1 | Piperidine derivatives and drugs containing these derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | claimed |
| EP-1308440-A1 | PIPERIDINE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-07 | — | — | EP | claimed |
| US-7649095-B2 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044036-A1 | Piperidine derivatives and drugs containing these derivatives as active ingredient | PDE4A, PDE4B, PDE4D | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20060189656-A1 | Piperidine derivatives and agent comprising the derivative as active ingredient | PDE4A, PDE4B, PDE4D | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.